高三酰甘油血症是临床常见的血脂紊乱类型，其中严重高三酰甘油血症与急性胰腺炎发病风险升高密切相关。当前严重高三酰甘油血症的治疗面临诸多挑战，因此许多新型治疗药物应运而生。载脂蛋白C3（APOC3）抑制剂、血管生成素样蛋白家族（ANGPTL）抑制剂、成纤维细胞生长因子21（FGF21）类似物、胰高血糖素样肽-1受体激动剂（GLP-1RA）、微粒体三酰甘油转移蛋白（MTP）抑制剂、人瘦素类似物、法尼醇X受体（FXR）激动剂在临床上广泛用于严重高三酰甘油血症的治疗。总结了严重高三酰甘油血症新型治疗药物的研究进展，为临床个体化治疗方案提供参考依据。

Hypertriglyceridemia is a common type of dyslipidemia in clinical practice, with severe hypertriglyceridemia being closely associated with an increased risk of acute pancreatitis. Current treatments for severe hypertriglyceridemia face numerous challenges, leading to the emergence of many novel therapeutic drugs. Apolipoprotein C3 (APOC3) inhibitors, angiopoietin-like protein family (ANGPTL) inhibitors, fibroblast growth factor 21 (FGF21) analogs, glucagon-like peptide-1 receptor agonist (GLP-1RA), microsomal triglyceride transfer protein (MTP) inhibitors, human leptin analogs, and farnesoid X receptor (FXR) agonists are widely used in clinical management of severe hypertriglyceridemia. This article summarizes the research progress on new drugs for severe hypertriglyceridemia, providing a reference for individualized clinical treatment strategies.